PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2024-09-09

Date Title Company
09-Sep-2024 The Center for Immunology Science and Immunology Diagnostics Announce a Major Breakthrough Discovery: DNA-Based Proof of the Disease of Fibromyalgia AccessWire
09-Sep-2024 Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis AccessWire
09-Sep-2024 CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress AccessWire
09-Sep-2024 CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress CureVac
09-Sep-2024 Meso Numismatics Announces Cellgenic’s Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September Newswire
09-Sep-2024 Interactive Strength Inc. (Nasdaq: TRNR) to Present at the H.C. Wainwright 26th Annual Global Investment Conference and Meet Institutional Investors in New York from September 9th to 11th AccessWire
09-Sep-2024 Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada AccessWire
09-Sep-2024 Sale of Gentronix to Danish group provides an exit for investor Mercia Ventures Mercia Ventures
09-Sep-2024 Provepharm launches Blumyne™ surgical dye in UK Andrew Lloyd Associates
09-Sep-2024 Animal Feed Enzymes Market Growth, Trends, and Forecast: Key Insights and Projections Till 2032 Ameco Research
09-Sep-2024 Nurse Call Systems Market is Likely to Grasp the CAGR of 9.5% During the Forecast Period of 2024 to 2032 Acumen Research and Consulting
09-Sep-2024 DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors Andrew Lloyd Associates
09-Sep-2024 VIVES IUF Fund raises additional €5M capital from Luxembourg Future Fund 2 Andrew Lloyd Associates
09-Sep-2024 Sports Nutrition Market Projected Growth from USD 53.41 Billion in 2023 to USD 76.8 Billion by 2030, with a CAGR of 5.6 Percentage MAXIMIZE MARKET RESEARCH PVT. LTD.
09-Sep-2024 Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson AccessWire